Reporting owner · CIK 0002148331

WSLS EMP ONSHORE INVESTMENTS, L.P.

SEC Form 4 history for the last 180 days across 1 company, 35 transactions and 1 filing.

10%Attovia Therapeutics, Inc.
Open-market transaction mix26% buys8 buys · 23 sales

Period: Last 180 days

Trade dates in this period: Aug 5, 2026 – Aug 6, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$12.5M8 purchases
Selling$2.25M23 sales
Net value+$10.3MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
WSLS EMP ONSHORE INVESTMENTS, L.P. transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$25.8kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$8.81kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$154kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$14.8kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$16.5kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$2.21kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$10.3kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$4.42kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$74.9kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$34.3kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$4.41kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$29.3kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$9.78kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
−$21.8kView disclosure →
ATTOAttovia Therapeutics, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
$1.79MView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a buy at Attovia Therapeutics, Inc. on Aug 6, 2026 valued at $8,500,000.

Review SEC filing
Latest sale

The insider reported a sale at Attovia Therapeutics, Inc. on Aug 5, 2026 valued at $1,607,834.72.

Review SEC filing

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Aug 2026823$12,533,073.84$2,251,657.70+$10,281,416.14

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$477k
Median P/S size$25.8k
Direct0
Indirect35
Aug 6, 2026unknown

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

27 observations · Aug 5, 2026 – Aug 6, 2026. Window ends at the latest available report, not today.

Selected observation · Aug 6, 20263,020,632 shares reportedAmended filing
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 5, 202685,000Aug 28, 2026Amended transaction
Aug 5, 202684,012Aug 28, 2026Amended transaction
Aug 5, 202683,565Aug 28, 2026Amended transaction
Aug 5, 202682,233Aug 28, 2026Amended transaction
Aug 5, 202682,033Aug 28, 2026Amended transaction
Aug 5, 202680,477Aug 28, 2026Amended transaction
Aug 5, 202677,075Aug 28, 2026Amended transaction
Aug 5, 202676,875Aug 28, 2026Amended transaction
Aug 5, 202676,395Aug 28, 2026Amended transaction
Aug 5, 202676,295Aug 28, 2026Amended transaction
Aug 5, 202675,542Aug 28, 2026Amended transaction
Aug 5, 202674,870Aug 28, 2026Amended transaction
Aug 5, 202667,900Aug 28, 2026Amended transaction
Aug 5, 202667,500Aug 28, 2026Amended transaction
Aug 5, 202666,320Aug 28, 2026Amended transaction
Aug 5, 202665,280Aug 28, 2026Amended transaction
Aug 5, 202664,980Aug 28, 2026Amended transaction
Aug 5, 202664,537Aug 28, 2026Amended transaction
Aug 5, 202664,337Aug 28, 2026Amended transaction
Aug 5, 202663,637Aug 28, 2026Amended transaction
Aug 5, 202662,474Aug 28, 2026Amended transaction
Aug 5, 202662,374Aug 28, 2026Amended transaction
Aug 5, 202655,611Aug 28, 2026Amended transaction
Aug 5, 20260Aug 28, 2026Amended transaction
Aug 6, 20262,042,134Aug 28, 2026Amended transaction
Aug 6, 20262,520,632Aug 28, 2026Amended transaction
Aug 6, 20263,020,632Aug 28, 2026Amended transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

WSLS EMP ONSHORE INVESTMENTS, L.P. Insider Activity FAQ

SEC Form 4 context

Who is WSLS EMP ONSHORE INVESTMENTS, L.P.?

WSLS EMP ONSHORE INVESTMENTS, L.P. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002148331.

Which companies has WSLS EMP ONSHORE INVESTMENTS, L.P. reported transactions for?

Attovia Therapeutics, Inc.

When was WSLS EMP ONSHORE INVESTMENTS, L.P.'s latest insider buy?

The insider reported a buy at Attovia Therapeutics, Inc. on Aug 6, 2026 valued at $8,500,000.

When was WSLS EMP ONSHORE INVESTMENTS, L.P.'s latest insider sale?

The insider reported a sale at Attovia Therapeutics, Inc. on Aug 5, 2026 valued at $1,607,834.72.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.